Reaction: Celecoxib to 1 product

Reaction type
Not Available
Major circulating metabolite?
  1. Davies NM, McLachlan AJ, Day RO, Williams KM: Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000 Mar;38(3):225-42. doi: 10.2165/00003088-200038030-00003. [Article]
  2. Paulson SK, Hribar JD, Liu NW, Hajdu E, Bible RH Jr, Piergies A, Karim A: Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. Drug Metab Dispos. 2000 Mar;28(3):308-14. [Article]
  3. Sandberg M, Yasar U, Stromberg P, Hoog JO, Eliasson E: Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol. 2002 Oct;54(4):423-9. [Article]
  4. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [Article]
  5. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE: Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012 Oct;92(4):414-7. doi: 10.1038/clpt.2012.96. [Article]
  6. Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE: Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012 Apr;22(4):310-8. doi: 10.1097/FPC.0b013e32834f94cb. [Article]
  7. Daily EB, Aquilante CL: Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep;10(9):1489-510. doi: 10.2217/pgs.09.82. [Article]
  8. FDA Approved Drug Products: CELEBREX (celecoxib) oral capsules [Link]
Not Available
Cytochrome P450 2C9Not AvailableNot Availableconfirmed
Cytochrome P450 3A4Not AvailableNot Availableconfirmed
Cytochrome P450 2D6Not AvailableNot Availableimplied
Cytochrome P450 2C8Not AvailableNot Availableimplied